Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 6/20 | 0.54 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.49 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.49 |
| ▸ | CALML3 | P27482 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SDHA | P31040 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763076 | 0.99 | MAOA (0.55) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL1393521 | 0.99 | MAOA (0.55) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL14763074 | 0.99 | MAOA (0.55) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL10196248 | 0.99 | MAOA (0.55) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL3179733 | 0.91 | MAOA (0.56) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL10259912 | 0.91 | MAOA (0.56) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL1393297 | 0.91 | MAOA (0.56) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL1394830 | 0.86 | MAOA (0.59) | MAOACALML3CYP3A4CYP2C9MAOB | |
| SCHEMBL10266866 | 0.86 | MAOA (0.64) | MAOACALML3CYP3A4MAOBLMNA | |
| SCHEMBL1393319 | 0.85 | MAOA (0.57) | MAOACALML3CYP3A4CYP2C9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| EP-1660465-B1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | MELINTA THERAPEUTICS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8895741-B2 | Process for the synthesis of biaryl oxazolidinones | MELINTA THERAPEUTICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | MELINTA SUBSIDIARY CORP. | 2013-03-14 | — | — | US | disclosed |
| US-8324398-B2 | Process for the synthesis of biaryl oxazolidinones | RIB-X PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-1656370-B1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB X PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705026-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | RIB-X PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-7456206-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2006-11-23 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA SUBSIDIARY CORP. | 2005-09-15 | — | — | US | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066076-A1 | Process for the Synthesis of Biaryl Oxazolidinones | PCNA, PGC, SBDS | MAOA 1272/4885MAOB 1133/4885PTGS1 203/4885 |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20060264426-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20100022772-A1 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDNONES | PCNA, PGC, MKI67 | MAOA 824/4885MAOB 743/4885PTGS1 206/4885 |
| US-20090118502-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20140073624-A1 | Biaryl Heterocyclic Compounds and Methods of Making and Using the Same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
| US-20050203147-A1 | Biaryl heterocyclic compounds and methods of making and using the same | PCNA, AADAC, MIF | MAOA 872/4885MAOB 994/4885PTGS1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.